{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:05:53Z","timestamp":1794963953899,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and pathologic complete response (0% residual viable tumor (RVT) in primary tumor (PT) and lymph nodes (LNs)), and is approved for treatment of resectable lung cancer. Pathologic response assessment after neoadjuvant therapy is the potential analog to radiographic response for advanced disease. However, %RVT thresholds beyond pathologic complete response and major pathologic response (\u226410% RVT) have not been explored. Pathologic response was prospectively assessed in the randomized, phase 3 CheckMate 816 trial (NCT02998528), which evaluated neoadjuvant nivolumab (anti-programmed death protein 1) plus chemotherapy in patients with resectable lung cancer. RVT, regression and necrosis were quantified (0\u2013100%) in PT and LNs using a pan-tumor scoring system and tested for association with EFS in a prespecified exploratory analysis. Regardless of LN involvement, EFS improved with 0% versus &gt;0% RVT-PT (hazard ratio\u2009=\u20090.18). RVT-PT predicted EFS for nivolumab plus chemotherapy (area under the curve\u2009=\u20090.74); 2-year EFS rates were 90%, 60%, 57% and 39% for patients with 0\u20135%, &gt;5\u201330%, &gt;30\u201380% and &gt;80% RVT, respectively. Each 1% RVT associated with a 0.017 hazard ratio increase for EFS. Combining pathologic response from PT and LNs helped differentiate outcomes. When compared with radiographic response and circulating tumor DNA clearance, %RVT best approximated EFS. These findings support pathologic response as an emerging survival surrogate. Further assessment of the full spectrum of %RVT in lung cancer and other tumor types is warranted. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02998528\">NCT02998528<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02660-6","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:02:26Z","timestamp":1698656546000},"page":"218-228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":201,"title":["Association between pathologic response and survival after neoadjuvant therapy in lung cancer"],"prefix":"10.1038","volume":"30","author":[{"given":"Julie Stein","family":"Deutsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cimino-Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-6344","authenticated-orcid":false,"given":"Patrick M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2708-1309","authenticated-orcid":false,"given":"Jonathan","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2363-9072","authenticated-orcid":false,"given":"Robert A.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gabrielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Illei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Jedrych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2813-3094","authenticated-orcid":false,"given":"Ludmila","family":"Danilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9987-6712","authenticated-orcid":false,"given":"Joel","family":"Sunshine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith M.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8203-5759","authenticated-orcid":false,"given":"Judith","family":"Bushong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junliang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Devas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Balli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2952-1830","authenticated-orcid":false,"given":"Tricia R.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-3342","authenticated-orcid":false,"given":"Alex S.","family":"Baras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8273-4395","authenticated-orcid":false,"given":"Janis M.","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"2660_CR1","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","volume":"15","author":"MD Hellmann","year":"2014","unstructured":"Hellmann, M. D. et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 15, e42\u2013e50 (2014).","journal-title":"Lancet Oncol."},{"key":"2660_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2023.01.002","volume":"177","author":"CM Blakely","year":"2023","unstructured":"Blakely, C. M. et al. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: a review. Lung Cancer 177, 59\u201372 (2023).","journal-title":"Lung Cancer"},{"key":"2660_CR3","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1470-2045(22)00451-X","volume":"23","author":"V Westeel","year":"2022","unstructured":"Westeel, V. et al. Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 23, 1180\u20131188 (2022).","journal-title":"Lancet Oncol."},{"key":"2660_CR4","doi-asserted-by":"publisher","first-page":"eaax0182","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2020","unstructured":"Topalian, S. L., Taube, J. M. & Pardoll, D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367, eaax0182 (2020).","journal-title":"Science"},{"key":"2660_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/JTO.0b013e31824c7d92","volume":"7","author":"G Mouillet","year":"2012","unstructured":"Mouillet, G. et al. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J. Thorac. Oncol. 7, 841\u2013849 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"2660_CR6","doi-asserted-by":"publisher","first-page":"S806","DOI":"10.1016\/j.annonc.2020.08.116","volume":"31","author":"NA Waser","year":"2020","unstructured":"Waser, N. A. et al. Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (rNSCLC): systematic literature review and meta-analysis. Ann. Oncol. 31, S806 (2020).","journal-title":"Ann. Oncol."},{"key":"2660_CR7","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell, T. R. et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann. Oncol. 29, 1853\u20131860 (2018).","journal-title":"Ann. Oncol."},{"key":"2660_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/1078-0432.CCR-19-2379","volume":"26","author":"JE Stein","year":"2020","unstructured":"Stein, J. E. et al. Pan-tumor pathologic scoring of response to PD-(L)1 blockade. Clin. Cancer Res. 26, 545\u2013551 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2660_CR9","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med."},{"key":"2660_CR10","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/oncolo\/oyab011","volume":"27","author":"W He","year":"2022","unstructured":"He, W. et al. Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma. Oncologist 27, e18\u2013e28 (2022).","journal-title":"Oncologist"},{"key":"2660_CR11","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1200\/JCO.20.00201","volume":"38","author":"SL Topalian","year":"2020","unstructured":"Topalian, S. L. et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial. J. Clin. Oncol. 38, 2476\u20132487 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2660_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26472-9","volume":"12","author":"JL Vos","year":"2021","unstructured":"Vos, J. L. et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat. Commun. 12, 7348 (2021).","journal-title":"Nat. Commun."},{"key":"2660_CR13","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","volume":"387","author":"ND Gross","year":"2022","unstructured":"Gross, N. D. et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N. Engl. J. Med. 387, 1557\u20131568 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2660_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34403-5","volume":"13","author":"Z Tang","year":"2022","unstructured":"Tang, Z. et al. The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Nat. Commun. 13, 6807 (2022).","journal-title":"Nat. Commun."},{"key":"2660_CR15","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976\u20131986 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2660_CR16","doi-asserted-by":"publisher","first-page":"e002485","DOI":"10.1136\/jitc-2021-002485","volume":"9","author":"R Leidner","year":"2021","unstructured":"Leidner, R. et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J. Immunother. Cancer 9, e002485 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2660_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33080-8","volume":"13","author":"WT Ju","year":"2022","unstructured":"Ju, W. T. et al. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat. Commun. 13, 5378 (2022).","journal-title":"Nat. Commun."},{"key":"2660_CR18","doi-asserted-by":"publisher","first-page":"e002568","DOI":"10.1136\/jitc-2021-002568","volume":"9","author":"RL Ferris","year":"2021","unstructured":"Ferris, R. L. et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J. Immunother. Cancer 9, e002568 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2660_CR19","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2660_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee, H. et al. Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer. N. Engl. J. Med. 389, 491\u2013503 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2660_CR21","doi-asserted-by":"publisher","first-page":"CT005","DOI":"10.1158\/1538-7445.AM2023-CT005","volume":"83","author":"JV Heymach","year":"2023","unstructured":"Heymach, J. V. et al. AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Cancer Res. 83, CT005 (2023).","journal-title":"Cancer Res."},{"key":"2660_CR22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","volume":"7","author":"A Pataer","year":"2012","unstructured":"Pataer, A. et al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J. Thorac. Oncol. 7, 825\u2013832 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"2660_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1046\/j.1365-2559.1998.00453.x","volume":"33","author":"KM Kerr","year":"1998","unstructured":"Kerr, K. M. et al. Partial regression in primary carcinoma of the lung: does it occur? Histopathology 33, 55\u201363 (1998).","journal-title":"Histopathology"},{"key":"2660_CR24","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1200\/JCO.2003.08.072","volume":"21","author":"JR Johnson","year":"2003","unstructured":"Johnson, J. R., Williams, G. & Pazdur, R. End points and United States Food and Drug Administration approval of oncology drugs. J. Clin. Oncol. 21, 1404\u20131411 (2003).","journal-title":"J. Clin. Oncol."},{"key":"2660_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","volume":"125","author":"TR Fleming","year":"1996","unstructured":"Fleming, T. R. & DeMets, D. L. Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. 125, 605\u2013613 (1996).","journal-title":"Ann. Intern. Med."},{"key":"2660_CR26","doi-asserted-by":"publisher","first-page":"e210008","DOI":"10.1148\/rycan.2021210008","volume":"3","author":"K Ruchalski","year":"2021","unstructured":"Ruchalski, K. et al. A primer on RECIST 1.1 for oncologic imaging in clinical drug trials. Radiol. Imaging Cancer 3, e210008 (2021).","journal-title":"Radiol. Imaging Cancer"},{"key":"2660_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"2660_CR28","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jtho.2023.07.017","volume":"18","author":"S Dacic","year":"2023","unstructured":"Dacic, S. et al. International Association for the Study of Lung Cancer study of reproducibility in assessment of pathologic response in resected lung cancers after neoadjuvant therapy. J. Thorac. Oncol. 18, 1290\u20131302 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2660_CR29","doi-asserted-by":"crossref","first-page":"A1511","DOI":"10.1136\/jitc-2023-007463","volume":"11","author":"JS Deutsch","year":"2023","unstructured":"Deutsch, J. S. et al. Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant IO trials (PATHdata): Interim analysis of a multi-institutional reproducibility study. J. Immunother. Cancer 11, A1511 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2660_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","volume":"15","author":"WD Travis","year":"2020","unstructured":"Travis, W. D. et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J. Thorac. Oncol. 15, 709\u2013740 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"2660_CR31","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.jtho.2020.11.009","volume":"16","author":"WD Travis","year":"2021","unstructured":"Travis, W. D., Dacic, S., Sholl, L. M. & Wistuba, I. I. Pathologic assessment of lung squamous cell carcinoma after neoadjuvant immunotherapy. J. Thorac. Oncol. 16, e9\u2013e10 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2660_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/BF01192200","volume":"123","author":"K Junker","year":"1997","unstructured":"Junker, K. et al. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy: histological assessment. J. Cancer Res. Clin. Oncol. 123, 469\u2013477 (1997).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2660_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/annonc\/mdz019","volume":"30","author":"JE Stein","year":"2019","unstructured":"Stein, J. E. et al. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. Ann. Oncol. 30, 589\u2013596 (2019).","journal-title":"Ann. Oncol."},{"key":"2660_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature19364","volume":"537","author":"R Eil","year":"2016","unstructured":"Eil, R. et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537, 539\u2013543 (2016).","journal-title":"Nature"},{"key":"2660_CR35","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.xcrm.2023.100947","volume":"4","author":"JS Deutsch","year":"2023","unstructured":"Deutsch, J. S. et al. Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. Cell Rep. Med. 4, 100947 (2023).","journal-title":"Cell Rep. Med."},{"key":"2660_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw, P. et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol. 11, 39\u201351 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"2660_CR37","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.21037\/tlcr-22-617","volume":"11","author":"W Liang","year":"2022","unstructured":"Liang, W. et al. International expert consensus on immunotherapy for early-stage non-small cell lung cancer. Transl. Lung Cancer Res. 11, 1742\u20131762 (2022).","journal-title":"Transl. Lung Cancer Res."},{"key":"2660_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty, P. J., Lumley, T. & Pepe, M. S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56, 337\u2013344 (2000).","journal-title":"Biometrics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02660-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02660-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02660-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T07:09:58Z","timestamp":1705907398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02660-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2660"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02660-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S.D. reports being named on a patent for system and method for annotating pathology images to predict patient outcome (US Provisional Patent Application: 63\/313,548; filed 2\/24\/2022). A.C.-M. reports receiving grants or contracts from Bristol Myers Squibb. M.P. reports receiving grants or contracts from AstraZeneca, Bristol Myers Squibb, Janssen, Pfizer, Roche and Takeda; and honoraria from AstraZeneca, Bristol Myers Squibb, MSD, Pfizer, Roche and Takeda. P.M.F. reports research funding received by his institution from AstraZeneca, BioNTech, Bristol Myers Squibb, Corvus, Kyowa, Novartis and Regeneron; trial steering committee membership for AstraZeneca, BioNTech, Bristol Myers Squibb and Corvus; participation in advisory boards and reimbursement from Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi, F-Star Therapeutics, G1 Therapeutics, Genentech, ITeos Therapeutics, Janssen, Merck, Novartis, Sanofi and Surface; and leadership positions at Mesothelioma Applied Research Foundation and LUNGevity Foundation. J. Spicer reports research funding received by his institution from AstraZeneca, Bristol Myers Squibb, CLS Therapeutics, Protalix Biotherapeutics, Merck and Roche; receiving support for the present manuscript from Bristol Myers Squibb; consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Merck, Novartis, Protalix Biotherapeutics, Regeneron, Roche and Xenetic Biosciences; honoraria from AstraZeneca, Bristol Myers Squibb and PeerView; participation on data safety monitoring\/advisory boards for the PUCC trial; and leadership positions at the Canadian Association of Thoracic Surgeons (unpaid). N.G. reports receiving consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda; and meeting\/travel support from Roche. R.A.A. reports receiving support for the present manuscript from Bristol Myers Squibb; grants or contracts from RAPT Therapeutics; consulting fees from AstraZeneca and MSD; and meeting\/travel support from Bristol Myers Squibb. E.G. reports research funding received by his institution from the National Cancer Institute and Congressionally Directed Medical Research Programs\u2014Department of Defense; honoraria from the LUNGevity Foundation; expert testimony provided to Covington and Burling; and holding mutual funds and exchange traded funds. P.I. reports receiving support for the present manuscript from Bristol Myers Squibb; grants or contracts from Bristol Myers Squibb; consulting fees from AbbVie, AstraZeneca, Merus, Roche and Sanofi; honoraria from Bristol Myers Squibb, Eli Lilly and Genentech; and being a shareholder of Bristol Myers Squibb. J. Sunshine reports grants or contracts from Palleon Pharmaceuticals. K.M.K. reports consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Takeda and Ventana; and honoraria from AstraZeneca, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Medscape, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Prime Oncology, Roche and Ventana. M.T. is an employee and shareholder of Bristol Myers Squibb. J.B. is an employee and shareholder of Bristol Myers Squibb. J.C. is an employee and shareholder of Bristol Myers Squibb. V.D. is an employee and shareholder of Bristol Myers Squibb. J.N. is an employee and shareholder of Bristol Myers Squibb. D.B. is an employee and shareholder of Bristol Myers Squibb; and reports being named on a patent of Bristol Myers Squibb. T.R.C. reports research funding received by her institution from Janssen; and honoraria from AstraZeneca, Society for Immunotherapy of Cancer and TotalCME. J.M.T. reports receiving support for the present manuscript from Bristol Myers Squibb; consulting fees from AstraZeneca, Bristol Myers Squibb, Merck and Roche; participation on advisory boards from AstraZeneca; and being named on a patent for a machine learning algorithm for irPRC. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}